Abstract
Using the structural information gathered from the X-ray structures of various cyclic urea/HIVPR complexes, we designed and synthesized many nonsymmetrical P2/P2'-substituted cyclic urea analogues. Our efforts concentrated on using an indazole as one of the P2 substituents since this group imparted enzyme (Ki) potency as well as translation into excellent antiviral (IC90) potency. The second P2 substituent was used to adjust the physical and chemical properties in order to maximize oral bioavailability. Using this approach several very potent (IC90 11 nM) and orally bioavailable (F% 93-100%) compounds were discovered (21, 22). However, the resistance profiles of these compounds were inadequate, especially against the double (I84V/V82F) and ritonavir-selected mutant viruses. Further modification of the second P2 substituent in order to increase H-bonding interactions with the backbone atoms of residues Asp 29, Asp 30, and Gly 48 led to analogues with much better resistance profiles. However, these larger analogues were incompatible with the apparent molecular weight requirements for good oral bioavailability of the cyclic urea class of HIVPR inhibitors (MW < 610).
References
Apr 6, 1995·Nature·J H CondraM Shivaprakash
Mar 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·D J KempfX P Kong
Apr 15, 1995·Lancet·G C YeeD T Lowenthal
Dec 30, 1994·Biochemical and Biophysical Research Communications·D L WinslowL T Bacheler
Feb 1, 1995·Journal of Virology·M MarkowitzD D Ho
Jan 10, 1995·Virology·H JacobsenJ Mous
Jul 1, 1994·Antimicrobial Agents and Chemotherapy·S Erickson-ViitanenJ L Meek
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·J P VaccaE Roth
Jan 21, 1994·Science·M R JacksonD B Williams
Dec 15, 1995·The Journal of Biological Chemistry·T Ridky, J Leis
Oct 1, 1995·Antimicrobial Agents and Chemotherapy·M BryantK Houseman
Apr 1, 1996·Chemistry & Biology·C N HodgeS Erickson-Viitanen
Oct 11, 1996·Journal of Medicinal Chemistry·W W WilkersonY Ru
Jan 17, 1997·Journal of Medicinal Chemistry·P K JadhavL T Bacheler
May 23, 1997·Journal of Medicinal Chemistry·G V De LuccaC H Chang
Jan 26, 1996·The Journal of Organic Chemistry·Michael E. PierceGeorge C. Emmett
Citations
Feb 19, 2000·Biochemical and Biophysical Research Communications·B KotamarthiS Miertus
Mar 28, 2008·Journal of Computer-aided Molecular Design·Rajni Garg, Barun Bhhatarai
Sep 17, 2009·Biological Trace Element Research·Fikret KaratasHaki Kara
Oct 1, 1998·Antiviral Research·A MollaD J Kempf
Nov 27, 1999·Bioorganic & Medicinal Chemistry Letters·M PatelS S Ko
Jul 15, 2011·Acta Crystallographica. Section E, Structure Reports Online·R J ButcherH S Yathirajan
Jul 15, 2011·Acta Crystallographica. Section E, Structure Reports Online·Ore KuyinuRay J Butcher
Nov 6, 2012·Acta Crystallographica. Section E, Structure Reports Online·S Rizwana BegumA G Anitha
Nov 13, 2012·PloS One·Divya YadavAnubhuti Pandey
Jun 15, 2004·Experimental Cell Research·Fares Al-EjehMarie Ranson
Oct 30, 2016·Chirality·Seyyed Rasul Mousavi
Nov 21, 2007·Organic & Biomolecular Chemistry·Giovanni PiersantiPaolo Carminati
Sep 25, 2019·Organic & Biomolecular Chemistry·Yan-Ling LiuJian-Zhong Chen
Aug 7, 2014·Molecular Diversity·Mir Rasul MousaviSayyed Mostafa Habibi-Khorassani
Mar 2, 2021·Medicinal Research Reviews·Yohan MalkiNicolas Masurier
Jan 15, 1999·Journal of Medicinal Chemistry·G V De LuccaI De Lucca
Mar 3, 2009·Journal of Medicinal Chemistry·Luciana GavernetLuis E Bruno-Blanch
Oct 28, 2005·Journal of Medicinal Chemistry·Patrizia MinettiGiorgio Tarzia
Feb 15, 2001·Journal of Medicinal Chemistry·W SchaalA Karlén
Sep 17, 2004·Journal of Medicinal Chemistry·Carol A ParishAlla Goldberg
Nov 14, 2000·The Journal of Organic Chemistry·K T Sprott, P R Hanson
May 24, 2000·Organic Letters·P W Baures